We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Sanofi (PK) | USOTC:SNYNF | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.50 | -0.52% | 95.50 | 92.83 | 99.47 | 95.50 | 94.864 | 94.864 | 412 | 21:02:47 |
As filed with the Securities and Exchange Commission on March 13, 2023
Registration No. 333-265050
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
POST-EFFECTIVE AMENDMENT NO. 1
TO FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
SANOFI
(Exact name of Registrant as specified in its charter)
Republic of France | Not Applicable | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification Number) |
46, avenue de la Grande Armée, 75017 Paris, France
(Address of Registrants principal executive offices)
ACTION 2022 SHAREHOLDING PLAN
(Full title of the plan)
Debora C. Pellicano
Vice President and Chief Financial Officer
Sanofi U.S. Services Inc.
55 Corporate Drive
Bridgewater, New Jersey 08807
Tel. No. +1 (908) 981-5000
(Name, address and telephone number of agent for service)
Copies to:
Sami Toutounji
Gide Loyrette Nouel A.A.R.P.I.
15 rue de Laborde
75008 Paris, France
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of large accelerated filer, accelerated filer, small reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☒ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☐ | Smaller reporting company | ☐ | |||
Emerging growth company | ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
EXPLANATORY NOTE: DEREGISTRATION OF SECURITIES
This Post-Effective Amendment No. 1 to the Registration Statement on Form S-8, Registration No. 333-265050 (the Registration Statement), is being filed to deregister certain shares of Sanofi (the Registrant) Ordinary Shares (the Shares) that were registered for issuance pursuant to the Action 2022 Shareholding Plan (the 2022 Plan). The Registration Statement, which was filed with the Securities and Exchange Commission on May 18, 2022, registered 500,000 Shares issuable pursuant to the 2022 Plan. The Registration Statement is hereby amended to deregister the 299,321 Shares that were previously registered and that remain unissued under the 2022 Plan.
SIGNATURES
THE REGISTRANT. Pursuant to the requirements of the U.S. Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused Post-Effective Amendment No. 1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Paris, France on March 13, 2023.
SANOFI | ||
By: | /s/ Roy Papatheodorou | |
Name: | Roy Papatheodorou | |
Title: | Executive Vice President, General Counsel & Head of Legal, Ethics & Business Integrity |
Note: In reliance upon Rule 478 under the U.S. Securities Act of 1933, as amended, no other person is required to sign this Post-Effective Amendment No. 1.
1 Year Sanofi (PK) Chart |
1 Month Sanofi (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions